-
How to break the red face killer at the top of the "ranking" of gynecological tumors? Oncologists teach you how to get out of the misunderstanding and break each one
Time of Update: 2023-01-07
Zhu Tao said: "At present, women's attitudes towards cervical cancer show two obvious trends, one is anxiety, HPV+TCT test is done every year, and the results are anxious as soon as they appear abnormal; The other is that it doesn't matter, some patients even three-year physical examination reports show abnormal cervical cancer indicators, ignoring them because they are asymptomatic, and some even give up cervical cancer screening and allow the disease to develop.
-
Lipzol ® combined with bevacizumab is approved in China for first-line maintenance therapy for HRD-positive advanced ovarian cancer
Time of Update: 2023-01-07
85)。 Academician Martin of the Chinese Academy of Engineering said: "The mortality rate of ovarian cancer ranks first among gynecological malignant tumors in China, and the emergence of PARP inhibitors and their application in first-line maintenance treatment programs for ovarian cancer may bring a new dawn to delay recurrence, prolong patient survival and improve cure.
-
Is surgery necessary for patients with newly diagnosed stage IV breast cancer?
Time of Update: 2023-01-07
A total of 350 patients with newly diagnosed stage IV breast cancer were randomized, and the experimental group received systemic therapy and local treatment according to their classification, and the control group only received corresponding systemic therapy.
-
The 2022 Chinese Oncology Conference "moved" to Hangzhou, hosted by Zhejiang Cancer Hospital
Time of Update: 2023-01-07
As the organizer, Cheng Xiangdong, Secretary of the Party Committee of Zhejiang Cancer Hospital, received the banner of the CCO Conference from Fan Daiming, Chairman of the Conference and Chairman of the Chinese Anti-Cancer Association - from this moment on, the CCO Conference officially entered "Hangzhou Time"!Due to the epidemic, the flag reception ceremony was also held in the "cloud".
-
Case challenge| 64-year-old man, what is the cause of back pain after modified radical mastectomy for breast cancer?
Time of Update: 2023-01-07
Present medical history: the patient complained of a right breast mass for 4 months 7 years ago, and after hollow core needle biopsy, the pathology showed estrogen receptor (ER) positive and HER2-negative breast cancer.
-
In the past 20 years, tumor treatment has undergone "earth-shaking" changes! Cheng Xiangdong: Starting from popular science, build the first line of defense against cancer
Time of Update: 2023-01-07
Opening words In November this year, the 2022 Chinese Oncology Congress will be held in Hangzhou. As an important part of the conference, the "Red Boat Leads the Healthy and Strong Country" science po
-
This article reviews the current status of first-line immunotherapy for NSCLC
Time of Update: 2023-01-07
3. Non-squamous & squamous NSCLC The CheckMate 9LA study showed that dual immunity (nivolumab + ipilimumab) combined with two cycles of chemotherapy compared with standard chemotherapy alone in the first-line treatment of EGFR/ALK-negative patients with advanced NSCLC significantly prolonged, regardless of PD-L1 expression level and tumor histological type, and has shown a trend of sustained survival benefit in the early stages.
-
ESMO 2022 "Re-challenged" immunotherapy results after first-line treatment progress Presented at ESMO: First Phase III Study
Time of Update: 2023-01-07
Details are as follows: Professor Mustafa Ozguroglu 1 background The EMPOWER-Lung 1 study showed that cemiplimab significantly improved overall survival (OS) with an acceptable safety profile when treated with advanced NSCLC with first-line monotherapy compared with chemotherapy.
-
The magazine's cutting-edge Chinese strong voice: Professor Zhou Caicun, Professor Wu Yilong, Professor Wang Jie led the research and won the JTO and JCO
Time of Update: 2023-01-07
Survival analysis conclusion Adebrelimab + albumin paclitaxel + carboplatin neoadjuvant therapy has shown a high MPR rate and a good safety profile in patients with resectable NSCLC, and a phase III study will be carried out based on the results of phase Ib studies.
-
Research on the topic of "Heart Inheritance - Big Coffee Dialogue" - those things about the diagnosis and treatment of lung cancer
Time of Update: 2023-01-07
From "the first killer of tumors" to "chronic disease management", how should lung cancer diagnosis and treatment "target" the timing and exert precise force? In this issue, we follow Professor Wang Z
-
Professor Xiang Yi: Lung cancer - precision treatment, breathing first
Time of Update: 2023-01-07
The 2022 national cancer report shows that lung cancer has an annual incidence of 828,000 people and an annual death of 657,000, ranking first in malignant tumors [1], which is a disease that seriousl
-
It's time for China to innovate! Professor Cheng Ying and ASTRUM-005 research were listed in international authoritative journals, refreshing the survival height of SCLC
Time of Update: 2023-01-07
335), one of the four top medical journals, published the full text online by Cheng Ying of Jilin Cancer Hospital Results of ASTRUM-005 (NCT04063163)1 in the global multicenter phase III clinical study of serplulimab (HLX10) in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) led by the professor.
-
Famous coffee meeting room big coffee face to face, from the drug safety to see the "way of using troops" of breast cancer ADC drugs
Time of Update: 2023-01-07
In recent years, with the deepening of clinical research on breast cancer and the continuous change of therapeutic drugs, the prognosis and survival of breast cancer patients have been continuously im
-
The 2022 ESMO Roundtable sent Professor Lu Shun to lead a team of experts to talk about immunity
Time of Update: 2023-01-07
The European Society for Medical Oncology (ESMO) Congress is a prestigious and influential oncology conference in Europe, and the ESMO Congress 2022 has successively announced many innovative therapie
-
ESMO 2022 Phase III CROWN Study 3-year follow-up results updated, Asian subgroup data published
Time of Update: 2023-01-07
Landmark analysis Conclusion: The follow-up results of the phase III CROWN study showed that in patients with and without brain metastases NSCLC at baseline, the intracranial disease progression time was better in the lorlatinib group than in the crizotinib group, and the CNS adverse events led to discontinuation of treatment in only 2 patients.
-
ESMO Pre-Research Alert| Advances in ER+/HER2-advanced/metastatic breast cancer endocrine therapy
Time of Update: 2023-01-07
Subgroup Analysis of the Phase 220P-III EMERALD Study: Oral Selective Estrogen Receptor Degrader (SERD) Elacestrant versus Fulvestrant or Aromatase Inhibitor (AI) Monotherapy for ER+/HER2-Advanced/Metastatic Breast Cancer (mBC) background The EMERALD clinical trial showed that elacestrant significantly prolonged progression-free survival (PFS) compared with standard endocrine therapy (SOC) in patients with ER+/HER2-mBC who had progressed after prior endocrine therapy and CDK4/6i inhibitor (CDK4/6i) and was tolerated toxicity.
-
FDA Alert| Selpercatinib accelerates approval for RET gene fusion-positive locally advanced or metastatic solid tumors
Time of Update: 2023-01-07
On September 21, 2022, the U. S. Food and Drug Administration (FDA) accelerated approval of the Selpercatinib extended indication for the treatment of patients with locally advanced or metastatic soli
-
Nutritional support for the treatment of cancer patients and between treatments
Time of Update: 2023-01-07
Editor: Traveler Yimaitong edited and sorted, please do not reprint without authorization. In the past half century, malignant tumors have become a common life-threatening disease in China, malnutriti
-
Once you break in, life should be fearless| Professor Jiang Zefei was a guest on "Medical Road Xinghe" and talked freely about this "medical" road
Time of Update: 2023-01-07
Breaking – Initiating a voting system for guideline discussions Professor Jiang Zefei: Let everyone have a fair opportunity to express themselves, reflect the opinions of doctors in different regions and levels, and the accessibility of diagnosis and treatment products.
-
The 2022 International Multi-center Clinical Trial Summit Forum (Jinling Multinational Corporations) is about to begin!
Time of Update: 2023-01-07
Multi-regional Clinical Trials (MRCT) has gradually become an efficient mode for the global simultaneous research and development of new drugs and new medical devices, and more and more multinational
